- Home
- MYGN vs CMRC Comparison
MYGN vs CMRC Comparison
Compare MYGN & CMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- CMRC
- Stock Information
- Founded
- MYGN 1991
- CMRC 2009
- Country
- MYGN United States
- CMRC United States
- Employees
- MYGN N/A
- CMRC N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CMRC
- Sector
- MYGN Health Care
- CMRC
- Exchange
- MYGN Nasdaq
- CMRC Nasdaq
- Market Cap
- MYGN 423.1M
- CMRC 359.6M
- IPO Year
- MYGN 1995
- CMRC 2020
- Fundamental
- Price
- MYGN $6.02
- CMRC $4.85
- Analyst Decision
- MYGN Hold
- CMRC Strong Buy
- Analyst Count
- MYGN 13
- CMRC 1
- Target Price
- MYGN $13.50
- CMRC $10.00
- AVG Volume (30 Days)
- MYGN 2.4M
- CMRC 982.2K
- Earning Date
- MYGN 08-05-2025
- CMRC 07-31-2025
- Dividend Yield
- MYGN N/A
- CMRC N/A
- EPS Growth
- MYGN N/A
- CMRC N/A
- EPS
- MYGN N/A
- CMRC N/A
- Revenue
- MYGN $832,900,000.00
- CMRC $337,541,000.00
- Revenue This Year
- MYGN N/A
- CMRC $5.06
- Revenue Next Year
- MYGN $6.64
- CMRC $5.25
- P/E Ratio
- MYGN N/A
- CMRC N/A
- Revenue Growth
- MYGN 3.83
- CMRC 4.06
- 52 Week Low
- MYGN $3.76
- CMRC $4.14
- 52 Week High
- MYGN $29.30
- CMRC $7.99
- Technical
- Relative Strength Index (RSI)
- MYGN 62.34
- CMRC N/A
- Support Level
- MYGN $5.23
- CMRC N/A
- Resistance Level
- MYGN $6.07
- CMRC N/A
- Average True Range (ATR)
- MYGN 0.39
- CMRC 0.00
- MACD
- MYGN 0.05
- CMRC 0.00
- Stochastic Oscillator
- MYGN 81.27
- CMRC 0.00
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.